Literature DB >> 12099753

Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

Esteban C Nannini1, Michael Keating, Peter Binstock, George Samonis, Dimitrios P Kontoyiannis.   

Abstract

Execpt in patients with AIDS, disseminated MAC infection has been rare. We describe a patient with chronic lymphatic leukemia who developed disseminated cutaneous MAC lesions refractory to conventional antimycrobial therapy. The lesions responded to the addition of compounds that were recently discovered to have anti-MAC activity (linezolid, moxifloxacin) as well as GM-CSF. Copyright 2002 The British Infection Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12099753     DOI: 10.1053/jinf.2002.0970

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  13 in total

1.  Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex.

Authors:  Toshiaki Shimizu; Haruaki Tomioka
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Reconsidering some approved antimicrobial agents for tuberculosis.

Authors:  Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

3.  In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.

Authors:  Lucio Vera-Cabrera; Barbara A Brown-Elliott; Richard J Wallace; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Carmen A Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

4.  Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria.

Authors:  Lia Danelishvili; Martin Wu; Lowell S Young; Luiz E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.

Authors:  Luiz E Bermudez; Nima Motamedi; Christopher Chee; Gyulnar Baimukanova; Peter Kolonoski; Clark Inderlied; Priscilla Aralar; Guoqiang Wang; Ly Tam Phan; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

6.  SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.

Authors:  Luiz E Bermudez; Peter Kolonoski; Lianne E Seitz; Mary Petrofsky; Robert Reynolds; Martin Wu; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Use of mefloquine in multidrug-resistant Mycobacterium avium complex pulmonary disease in an HIV-negative patient.

Authors:  Juan Ramirez; Carol Mason; Juzar Ali
Journal:  Curr Ther Res Clin Exp       Date:  2007-11

8.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

9.  Mixed Mycobacterium Avium-Intracellulare and Serratia Marcescens Cellulitis of the Breast in an HIV-Negative Patient with Breast Cancer: A Case Report.

Authors:  Andreas Kyvernitakis; Jacques Azzi; Dimitrios P Kontoyiannis
Journal:  Cureus       Date:  2016-06-09

10.  Multidrug- and extensively drug-resistant tuberculosis, Germany.

Authors:  Barbara Eker; Johannes Ortmann; Giovanni B Migliori; Giovanni Sotgiu; Ralf Muetterlein; Rosella Centis; Harald Hoffmann; Detlef Kirsten; Tom Schaberg; Sabine Ruesch-Gerdes; Christoph Lange
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.